Drug Development RFP
Funds early-stage drug and device studies with novel mechanisms for Alzheimer’s and related dementias, emphasizing strong scientific rationale and innovative, biologically relevant approaches.
Funder: Alzheimer's Drug Discovery Foundation
Due Dates: September 14, 2026: Letter of Intent deadline
Funding Amounts: Up to $5,000,000 per award; multi-year awards; direct costs only; milestone-based payments.
Summary: Supports IND-enabling studies and early-phase clinical trials for innovative drugs and devices targeting Alzheimer’s disease and related dementias.
Description
This opportunity funds investigational new drug (IND)-enabling studies and early-stage clinical trials for novel pharmacological interventions and devices for Alzheimer’s disease and related dementias. The program prioritizes projects with strong scientific rationale, robust preliminary data, and innovative mechanisms or modes of action tied to the biology of aging. Eligible approaches include small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, stem cells, and repurposed drugs. Projects must demonstrate novelty and biological relevance, supported by genetic, molecular, and preclinical evidence. Collaboration and multidisciplinary approaches are encouraged, and all funded clinical trials must be registered and report results as required.
